.gif) VIARTIS
|
|||||
|
PARKINSON'S DISEASE NEWS |
|||||
|
|
18th February 2013 - News release COGANE FAILS CLINICAL TRIALS FOR PARKINSON'S DISEASE Phytopharm announced the results of the Phase II, randomised, double blind, placebo controlled, dose-ranging trial of Cogane in unmedicated patients with early-stage Parkinson’s Disease. Cogane was found to have no beneficial effects at all on Parkinson's Disease symptoms. For more information go to the News release
|
|
|||
|
Parkinson's Disease News details all significant new research, news reports, new books, and new resources concerning Parkinson's Disease and those medical disorders that often coincide with Parkinson's Disease. It is compiled from an analysis of all newly published research, news reports, new clinical trials, all newly published books, and new web sites. A summary and analysis of the new research are provided, as well as links to the complete abstracts and news reports
|
|||||
.gif) |
|||||
| ©2006-2013 Viartis | |||||
| 2015-08-25 02:55:59 | |||||
| [email protected] | |||||
Cogane,
which can be taken orally, readily crosses the blood-brain barrier and has been
shown to stimulate the release of GDNF. GDNF can indirectly stimulate the
formation of dopamine, the substance whose insufficiency causes Parkinson's
Disease. However, GDNF deficiency has never been shown to be the cause of
Parkinson's Disease. Previous studies claiming efficacy for Cogane in
Parkinson's Disease were only carried out in Macaque monkeys who did not
actually have Parkinson's Disease. For a printable version of this article
E-MAIL NOTIFICATION : If you would like to be
notified by e-mail when any new articles are added to Parkinson's Disease News, please merely
e-mail
